Bactiguard
Zimmer Biomet terminates agreement for multiple orthopedic product segments - trauma agreement remains in effect
Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with the US Food and Drug Administration (FDA) than initially expected by Zimmer Biomet.
There will be no negative financial impact for Bactiguard for 2024 related to this termination. Bactiguard is in dialogue with the team at Zimmer Biomet to evaluate further details and the impact of the termination and will revert with more information once available.
The partnership with Zimmer Biomet within the trauma product segment, related to the agreement signed in 2019, remains in effect.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, 2024-10-02 at 10:40 CET.
| Datum | 2024-10-02, kl 10:40 |
| Källa | Cision |
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.